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In utero fetal exposure to high oestrogen levels has been proposed
as a causal factor in the aetiology of female breast cancer
(Trichopoulos, 1990). Isolating this effect in females is compli-
cated by a variety of postnatal hormonal exposures including
menarche, menstrual cycles, pregnancies, menopause and exoge-
nous hormones. Since breast cancer in males is considered to be
essentially the same disease as in females (based on similarities in
histopathology (Thomas, 1993), genetics (Friedman et al, 1997;
Mavraki et al, 1997) and other predisposing factors (Sasco et al,
1993)), any increased risk from exposure to high levels of
oestrogen in utero should be easier to detect in males due to the
absence of these complicating postnatal factors. During gestation,
all twins are exposed to levels of unbound endogenous oestrogen
that are approximately two-fold greater than for singletons
(TambyRaja and Ratnam, 1981; Thomas et al, 1998), and should
therefore be at higher risk for male breast cancer assuming the ‘in
utero exposure hypothesis’ to be true (London, 1993). We have
analysed the occurrence of male breast cancer (MBC) in 115 235
male twins followed for more than 3.5 million person-years at risk
to test the hypothesis that prenatal exposure to high levels of
oestrogen increases the risk of MBC.
Male-male twin pairs were identified from population-based
twin registers in three Nordic countries (Denmark, Finland,
Sweden) as well as a large US twin register (the National
Academy of Science – National Research Council Twin registry).
The Danish cohort consisted of 8970 twin individuals born
between 1870–1930 who were both alive on January 1, 1943
(Hauge, 1981). The Finnish twin cohort included 15 813 male
twins who were born between 1880–1958 and were both alive and
living in Finland on December 31, 1975 (Verkasalo et al, 1999a).
We also analysed two sub-cohorts of the Swedish twin registry: an
older cohort comprising 9680 male twins born between 1886 and
1925 who were both alive in 1961 (Cederlof et al, 1977) and a
younger cohort of 11964 male twins of known zygosity born
between 1926 and 1958 who were both alive in 1971, and 11826
twins of unknown zygosity born 1926–67 (Medlund et al, 1976).
For the Swedish twin registry only, we were also able to ascertain
a further cohort of 13 820 male co-twins from unlike-sex twins
born 1926–1967. In each of these Nordic cohorts, zygosity was
determined by self-reported questionnaire items and incident cases
of MBC (both fatal and non-fatal) were identified through record
linkage to the national cancer registry in each country for which
ascertainment is virtually complete (Lichtenstein et al, 2000).
The US twin cohort was derived from the National Academy of
Science – National Research Council Twin registry (Jablon et al,
1967), and comprised 31 848 white male twins who were born in
the years 1917–1927 inclusive and served in the US military
during World War 2. Unlike the Nordic cohorts, this historical
cohort was followed up only for mortality using cause of death
certificates from the Department of Veterans Affairs and the
National Death Index files.
For all four cohorts, observed numbers of cancers and person-
years at risk were calculated according to age (five-year age-
groups), calendar period (varied by country) and zygosity
(monozygous (MZ), dizygous (DZ) and unknown zygosity (UZ)).
We stratified the analyses by zygosity firstly to determine whether
the risk of MBC differed between MZ and DZ twins, and secondly
because we were concerned that the follow-up information for
those coded as ‘unknown zygosity’ may have differed qualita-
tively from those of known zygosity.
Calculation of person-years began at compilation of the cohort
and ended at death or closure of follow-up (Denmark: 1943–93;
Finland: 1976–95; Sweden: 1961 (older cohort)/1971 (younger
cohort)–1996; US: 1946–95). The expected numbers were calcu-
lated by multiplying the stratum-specific numbers of person-years
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either by the corresponding cancer incidence in the appropriate
Nordic country or by death rate of US white male population. The
standardized rate ratios (SRR) were computed by dividing the
observed number of cases by the number expected; they denote
standardized incidence ratios for the Nordic cohorts and standard-
ized mortality ratios for the US cohort. The 95% confidence inter-
vals (CI) were calculated from the Poisson distribution. We
calculated the Breslow–Day statistic to test for heterogeneity of
the SRR across studies (Breslow and Day, 1987).
Overall, we observed 11 cases of MBC versus 16.16 expected
cases (Table 1). We found no evidence that male twins were at
increased risk for MBC when compared with the general popula-
tion (SRR 0.68, 95% CI 0.34–1.22). There was no evidence of
heterogeneity of the SRRs across studies (χ 2 = 3.66, P = 0.30), and
restricting the analysis to incident cases of MBC from the similar
Nordic cohorts made no substantive difference to the SRR (9 cases
observed, 11.82 expected, SRR 0.76, 95% CI 0.35–1.45).
The occurrence of MBC appeared similarly reduced among MZ
(SRR 0.58, 95% CI 0.12–1.70) and DZ twins (SRR 0.66, 95% CI
0.24–1.43) compared with population expectation, while for male
twins of unknown zygosity, the SRR showed a marginal, non-
significant increase (1.05, 95% CI 0.13–3.80). There were no
cases of MBC observed among the Swedish cohort of 13 820 male
co-twins from unlike-sex pairs during 337 176 person-years at risk
(0.82 expected, SRR 0, 95% CI 0–4.50).
We have found no support for the notion that male offspring of
twin pregnancies are at higher risk for breast cancer than the
general population. Our findings agree with a recent meta-analysis
of breast cancer in female twins, which found a pooled standard-
ized incidence ratio of 1.05 (95% CI 0.99–1.1) and thus excluded
any important increase in breast cancer risk among female twins of
all ages (Verkasalo et al, 1999b). The meta-analysis was based on
1323 cases of female breast cancer diagnosed among three Nordic
twin cohorts. On the other hand, a recent US study reported a
relative risk of 1.72 (95% CI 1.22–2.42) for breast cancer among
postmenopausal female twins based upon 35 cases of breast cancer
(5 cases among MZ, 23 among DZ and 7 among twins of unknown
zygosity) (Cerhan et al, 2000).
Our record-linkage study approach is the most efficient
epidemiological design to test our hypothesis. Nevertheless, even
though we pooled data from three national twin registers and a
further large population-based register, our study had limited
power to provide precise risk estimates. This limitation will apply
to all studies attempting to investigate the ‘in utero exposure
Table 1 Occurrence of breast cancer among male twins, by country
Country No of twin PYARa Obsb Expc SRRd 95% CIe
individuals
Denmark 1943–93 (born 1870–1930)
MZ6 2808 105 221 1 1.30 0.77 0.02–4.29
DZ 5256 198 688 3 2.25 1.33 0.28–3.90
UZ 906 28 877 0 0.33 0 0–11.2
Total 8970 332 786 4 3.88 1.03 0.39–2.75
Finland 1976–95 (born < 1958)
MZ 3770 68 817 0 0.31 0 0–11.9
DZ 8936 163 979 0 0.70 0 0–5.27
UZ 3107 52 874 2 0.28 7.16 0.87–25.9
Total 15 813 285 670 2 1.29 1.55 0.19–5.60
Sweden 1961/71–96 Older cohort (born 1886–1925)
MZ 3298 83 804 1 1.55 0.64 0.02–3.59
DZ 5966 153 938 2 2.72 0.74 0.09–2.66
UZ 416 10 410 0 0.19 0 0–19.4
Total 9680 248 152 3 4.46 0.67 0.14–1.97
Younger cohort (born 1926–58)
MZ 4584 112 268 0 0.33 0 0–11.2
DZ 7380 180 815 0 0.53 0 0–6.96
UZ 11 826 288 574 0 0.51 0 0–7.23
Total 23 790 581 657 0 1.37 0 0–2.69
Male co-twins from unlike sex pairs (born 1926–67) 13 820 337 176 0 0.82 0 0–4.50
All Nordic twin cohorts
MZ 14 460 370 110 2 3.49 0.58 0.07–2.07
DZ 41 358 1 034 596 5 7.02 0.71 0.23–1.66
UZ 16 255 380 735 2 1.31 1.53 0.19–5.52
Total 72 073 1 785 441 9 11.82 0.76 0.35–1.45
US 1946–95 (born 1917–27)
MZ 11 617 528 243 1 1.66 0.60 0.02–3.36
DZ 14 796 665 922 1 2.09 0.48 0.01–2.67
UZ 4507 194 781 0 0.59 0 0–6.25
Total 30 920 1 388 946 2 4.34 0.46 0.06–1.66
All twin cohorts
MZ 26 077 898 353 3 5.15 0.58 0.12–1.70
DZ 56 154 1 756 672 6 9.11 0.66 0.24–1.43
UZ 33 004 874 500 2 1.90 1.05 0.13–3.80
Total 115 235 3 529 525 11 16.16 0.68 0.34–1.22
aPerson-years at risk. bNumber of observed cases of MBC. cExpected number of cases of MBC based on age- and calendar-year incidence rates for each
country. dStandardized rate ratio (incidence for Nordic cohorts, mortality for US cohort). e95% confidence interval. fMZ, monozygous twins; DZ, dizygous twins;
UZ, twins of unknown zygosity.Breast cancer risk in male twins 1233
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hypothesis’ in MBC, due to the rarity of both the exposure and the
outcome. In particular, our estimate of the risk of MBC among
male co-twins of unlike-sex pairs lacks precision since only one
registry had assembled a cohort of this type. While other twin
cohorts certainly exist (Boomsma, 1998), very few combine the
characteristics of large sample size and long duration of follow-up
necessary to generate cases of this rare malignancy. Moreover, to
our knowledge, no other twin cohorts besides those involved in
this pooled analysis have directly assessed the occurrence of breast
cancer among male twins.
A frequent limitation of record-linkage methods is the inability
to adjust for potentially confounding factors other than age.
However, few risk factors are known for MBC and the population
prevalence of the commonly cited risk factors, such as
Klinefelter’s syndrome or exposure to ionizing radiation (Thomas,
1993), is very low and unlikely to account for the null findings of
the present study.
We conclude that if in utero exposure to high levels of oestrogen
is involved in the development of male breast cancer, then the
influence is likely to be very small.
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